Proven Effectiveness in 13 RCTs
FDA and CE Market-Ready Device
Fully Automated, AI-Powered Digital Treatment
Available in Nine Languages
The world’s most researched digital therapy program for depression. Proven effectiveness in 13 RCTs with a NNT of 3.6.
Clinically shown to reduce depressive symptoms as well as improve self-esteem and quality of life.
Fully automated treatment adapts to individual patient needs and fits into the therapy plans of all providers, payers and employers.
Developed by GAIA AG’s multidisciplinary team of experts in medicine, clinical psychology, psychotherapy and software development.
Provides Cognitive Behavioral Therapy (CBT) and other effective psychotherapeutic techniques.
Tailored to specific patient needs and cognitive capabilities. Accessible across all devices, anytime, anywhere.
RCTs demonstrate deprexis®’ effectiveness, safety and suitability.
Nine independent studies conducted with deprexis® have demonstrated its effectiveness as a standalone treatment and have confirmed the increase in benefits when deprexis® is added to existing care plans.
Depression is especially prevalent in patients with severe medical conditions and disorders. deprexis® has been shown to effectively treat depression as a comorbidity of epilepsy, multiple sclerosis and gambling disorder.
A study of 3,805 participants demonstrated using deprexis® significantly reduces the cost of treating depression for health insurers, while simultaneously reducing depressive symptoms and increasing quality of life in patients.
Gräfe et al.32227-1/abstract) (2017)
Multiple meta-analyses and systematic reviews have confirmed the scientific evidence gathered in 13 RCTs that deprexis® is an effective treatment for depression.
USA: University of Texas, Austin; Cedars Sinai Medical Center Los Angeles; University of Massachusetts Medical School
SWEDEN: The Karolinska Institute; Linkoping University
GERMANY: Charite Universitätsmedizin Berlin; Universität Trier; Universität Tübingen
UK: University of Cambridge; Kings College London; City University, London
FUNDING PARTNERS: the U.S. department of veteran affairs, the U.S. national multiple sclerosis society, the European Union, the European Commission, the German ministry of health, and the Brain and Behavior Research Foundation, the German Association of Psychotherapists (DPTV), major German health insurance companies and several other research centers, universities and hospitals across Europe, the U.S. and other regions.